Anti-EBNA-1 (EBV) Purified

*Cardinaud S, Starck SR, Chandra P, Shastri N: The synthesis of truncated polypeptides for immune surveillance and viral evasion. PLoS One. 2010 Jan 21;5 (1) :e8692., URL: https://www.ncbi.nlm.nih.gov/pubmed/20098683, *Fawzy S, Sallam M, Awad NM: Detection of Epstein-Barr virus in breast carcinoma in Egyptian women. Clin Biochem. 2008, 41 (7-8) :486-492., URL: https://pubmed.ncbi.nlm.nih.gov/18258188/, *Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P, Burns D, McAulay K, Turner M, Bellamy C, Amlot PL, Kelly D, MacGilchrist A, Gandhi MK, Swerdlow AJ, Crawford DH: Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicenter clinical trial. Blood 2007, 110 (4) :1123-31., URL: https://pubmed.ncbi.nlm.nih.gov/17468341/

The mouse monoclonal antibody E1-2.5 recognizes repetitive Gly-Ala region of the Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA-1) . EBNA-1 is the only viral protein consistently expressed in all malignancies associated with EBV.